Mainz Biomed NV
F:4TO

Watchlist Manager
Mainz Biomed NV Logo
Mainz Biomed NV
F:4TO
Watchlist
Price: 8 EUR Market Closed
Market Cap: 175.1m EUR

Operating Margin
Mainz Biomed NV

-2 575.7%
Current
-2 504%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 575.7%
=
Operating Profit
-17m
/
Revenue
659.9k

Operating Margin Across Competitors

No Stocks Found

Mainz Biomed NV
Glance View

Market Cap
175.1m EUR
Industry
Biotechnology

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 58 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

4TO Intrinsic Value
0.63 EUR
Overvaluation 92%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 575.7%
=
Operating Profit
-17m
/
Revenue
659.9k
What is the Operating Margin of Mainz Biomed NV?

Based on Mainz Biomed NV's most recent financial statements, the company has Operating Margin of -2 575.7%.

Back to Top